Tigermed (03347) has released its interim results for the 2026 fiscal year, revealing a net loss attributable to owners of the company of approximately RMB 413 million, marking a sharp swing from the profit recorded in the same period last year.

Revenue for the period reached RMB 3.7076 billion, reflecting a year-on-year increase of 14.1%. Gross profit stood at approximately RMB 1.021 billion, up 4.3% from the prior year, while the net loss attributable to shareholders translated into a loss per share of RMB 0.48.

Excluding non-recurring items, the net profit attributable to shareholders of the listed company was approximately RMB 278 million, representing a robust growth of 31.8% compared to the previous year.

According to the company's announcement, the reported loss was primarily driven by unrealized fair value losses of RMB 443 million on financial instruments, a non-cash and non-taxable item that significantly impacted the bottom line despite solid operational performance.